Related Experiment Video
Updated: Oct 13, 2025
Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
Published on: July 23, 2016
The brain targeted delivery of programmed cell death 4 specific siRNA protects mice from CRS-induced depressive
Yufeng Jia1, Xiao Zhuang1, Yi Zhang1
1Shandong Key Laboratory of Infection and Immunity, Department of Immunology, School of Basic Medical Sciences, Shandong University, 250012, Jinan, Shandong, China.
Abstract:
Depression is one of the most common psychiatric disorders. Recently, studies demonstrate that antidepressants generating BDNF not only maintain synaptic signal transmission but also repress neuroinflammatory cytokines such as IL-6 and IL-1β. Therefore, promoting BDNF expression provides a strategy for the treatment of depression. Our recent research has indicated that programmed cell death 4 (Pdcd4) is a new target for antidepressant treatment by facilitating BDNF. Herein, we modified Pdcd4 specific small interfering RNA (siPdcd4) with the rabies virus glycoprotein peptide (RVG/siPdcd4) which enables it cross the blood-brain barrier (BBB). We found that RVG/siPdcd4 complex was selectively delivered to neurons and microglia and silenced the expression of Pdcd4, thereby up-regulating the level of BDNF and down-regulating IL-6 and IL-1β expression. More importantly, RVG/siPdcd4 injection attenuated synaptic plasticity impairment and protected mice from CRS-induced depressive behavior. These findings suggest that RVG/siPdcd4 complex is a potential therapeutic medicine for depression.
Insights
This study introduces RVG/siPdcd4, a novel therapy that targets programmed cell death 4 (Pdcd4) to boost brain-derived neurotrophic factor (BDNF) levels. This approach effectively treats depression by reducing neuroinflammation and restoring synaptic function.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- Depression is a prevalent psychiatric disorder often linked to imbalances in neurotrophic factors and neuroinflammation.
- Brain-derived neurotrophic factor (BDNF) plays a crucial role in synaptic plasticity and neuronal survival, making it a key target for antidepressant therapies.
- Antidepressants that increase BDNF can modulate neuroinflammatory cytokines like IL-6 and IL-1β, offering a therapeutic strategy.
Purpose of the Study:
- To investigate programmed cell death 4 (Pdcd4) as a novel target for enhancing BDNF expression and treating depression.
- To develop and evaluate a targeted delivery system (RVG/siPdcd4) for crossing the blood-brain barrier (BBB) and silencing Pdcd4 in the brain.
- To assess the therapeutic efficacy of RVG/siPdcd4 in a mouse model of depression.
Main Methods:
- Development of a rabies virus glycoprotein peptide (RVG)-conjugated small interfering RNA targeting Pdcd4 (siPdcd4) for enhanced BBB penetration.
- In vivo administration of RVG/siPdcd4 to mice to assess its selective delivery to neurons and microglia.
- Measurement of Pdcd4, BDNF, IL-6, and IL-1β expression levels, as well as evaluation of synaptic plasticity and depressive behaviors in response to treatment.
Main Results:
- RVG/siPdcd4 selectively targeted neurons and microglia, effectively silencing Pdcd4 expression within the brain.
- Treatment with RVG/siPdcd4 led to a significant upregulation of BDNF and downregulation of pro-inflammatory cytokines IL-6 and IL-1β.
- RVG/siPdcd4 administration ameliorated synaptic plasticity deficits and protected mice against chronic unpredictable stress (CRS)-induced depressive behaviors.
Conclusions:
- Targeting Pdcd4 with the RVG/siPdcd4 complex represents a promising strategy for boosting BDNF levels and combating depression.
- The RVG/siPdcd4 complex demonstrates effective blood-brain barrier penetration and selective delivery, highlighting its potential as a novel therapeutic agent.
- These findings suggest that RVG/siPdcd4 holds significant potential as a new pharmacological treatment for depression.
